<DOC>
	<DOCNO>NCT01763580</DOCNO>
	<brief_summary>To compare therapeutic effect tacrolimus combination low-dose corticosteroid high-dose corticosteroid alone patient minimal-change nephrotic syndrome .</brief_summary>
	<brief_title>A Study Evaluate Effect Tacrolimus Corticosteroid Combination Therapy Patients With Minimal Change Nephrotic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Nephrosis , Lipoid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>patient diagnose initial relapsed primary minimalchange nephrotic syndrome patient whose urine proteincreatinine ratio ( UPCR ) 3.0 patient whose eGFR less 30 ml/min/1.73 m2 patient treat immunosuppressant , tacrolimus , cyclosporine , cyclophosphamide ( Cytoxan ) , mizoribine ( Bredinin ) , levamisole , azathioprine , mycophenolate mofetil , rituximab , within two week study patient 10 mg prednisolone equivalent dose steroid administer daily within two week study patient pregnant , breastfeeding , plan pregnant breastfeed within six month study completion , want use contraceptive method patient hypersensitive investigational drug macrolide , azithromycin , clarithromycin , roxithromycin patient treat live vaccine within four week study patient whose liver panel laboratory test result three time normal range , acute hepatitis patient whose serum bilirubin clinically significantly high 3.6 mg/dL 1 month patient significant general disease make inappropriate participate study adjudge investigator ( e.g. , cardiovascularacute myocardial infarction , heart failure [ classify New York Heart Association { NYHA } class III ] , hepatic/gastrointestinal/neurologic disease , blood disorder , cancer , infection , renal disorder minimalchange nephrotic syndrome , rheumatic arthritis pneumonia interstitials ) patient genetic problem galactose intolerance , Lapp lactose deficiency , glucosegalactose malabsorption patient another investigational drug administer within 30 day enrollment study patient participate past phase study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glomerulonephritis</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Nephrotic syndrome</keyword>
</DOC>